296 related articles for article (PubMed ID: 29354490)
1. The contemporary role and impact of urine-based biomarkers in bladder cancer.
Duquesne I; Weisbach L; Aziz A; Kluth LA; Xylinas E;
Transl Androl Urol; 2017 Dec; 6(6):1031-1042. PubMed ID: 29354490
[TBL] [Abstract][Full Text] [Related]
2. Urine markers for detection and surveillance of bladder cancer.
Xylinas E; Kluth LA; Rieken M; Karakiewicz PI; Lotan Y; Shariat SF
Urol Oncol; 2014 Apr; 32(3):222-9. PubMed ID: 24054865
[TBL] [Abstract][Full Text] [Related]
3. Can urinary biomarkers replace cystoscopy?
Maas M; Bedke J; Stenzl A; Todenhöfer T
World J Urol; 2019 Sep; 37(9):1741-1749. PubMed ID: 30283995
[TBL] [Abstract][Full Text] [Related]
4. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.
Tilki D; Burger M; Dalbagni G; Grossman HB; Hakenberg OW; Palou J; Reich O; Rouprêt M; Shariat SF; Zlotta AR
Eur Urol; 2011 Sep; 60(3):484-92. PubMed ID: 21684071
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
6. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.
Lotan Y; Black PC; Caba L; Chang SS; Cookson MS; Daneshmand S; Kamat AM; McKiernan JM; Pruthi RS; Ritch CR; Steinberg GD; Svatek RS; Zwarthoff EC
Eur Urol Oncol; 2018 Aug; 1(3):223-230. PubMed ID: 31102625
[TBL] [Abstract][Full Text] [Related]
7. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
8. Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma.
Miyake M; Owari T; Hori S; Nakai Y; Fujimoto K
Res Rep Urol; 2018; 10():251-261. PubMed ID: 30588457
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus.
Schmitz-Dräger BJ; Droller M; Lokeshwar VB; Lotan Y; Hudson MA; van Rhijn BW; Marberger MJ; Fradet Y; Hemstreet GP; Malmstrom PU; Ogawa O; Karakiewicz PI; Shariat SF
Urol Int; 2015; 94(1):1-24. PubMed ID: 25501325
[TBL] [Abstract][Full Text] [Related]
10. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in Bladder Cancer Surveillance.
Sugeeta SS; Sharma A; Ng K; Nayak A; Vasdev N
Front Surg; 2021; 8():735868. PubMed ID: 34651010
[No Abstract] [Full Text] [Related]
12. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
13. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder.
Xylinas E; Kluth LA; Lotan Y; Daneshmand S; Rieken M; Karakiewicz PI; Shariat SF
Urol Oncol; 2014 Apr; 32(3):230-42. PubMed ID: 24332648
[TBL] [Abstract][Full Text] [Related]
14. Urine markers for bladder cancer surveillance: a systematic review.
van Rhijn BW; van der Poel HG; van der Kwast TH
Eur Urol; 2005 Jun; 47(6):736-48. PubMed ID: 15925067
[TBL] [Abstract][Full Text] [Related]
15. Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer.
Clinton T; Lotan Y
Rambam Maimonides Med J; 2017 Oct; 8(4):. PubMed ID: 28872454
[TBL] [Abstract][Full Text] [Related]
16. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.
Frantzi M; van Kessel KE; Zwarthoff EC; Marquez M; Rava M; Malats N; Merseburger AS; Katafigiotis I; Stravodimos K; Mullen W; Zoidakis J; Makridakis M; Pejchinovski M; Critselis E; Lichtinghagen R; Brand K; Dakna M; Roubelakis MG; Theodorescu D; Vlahou A; Mischak H; Anagnou NP
Clin Cancer Res; 2016 Aug; 22(16):4077-86. PubMed ID: 27026199
[TBL] [Abstract][Full Text] [Related]
18. The Efficient and Effective Use of Exfoliative Urinary Markers.
Whitson JM; Porten SP; Hussein AA; Meng MV
Urol Pract; 2016 May; 3(3):195-202. PubMed ID: 37592491
[TBL] [Abstract][Full Text] [Related]
19. Current Use and Promise of Urinary Markers for Urothelial Cancer.
Tabayoyong W; Kamat AM
Curr Urol Rep; 2018 Oct; 19(12):96. PubMed ID: 30328534
[TBL] [Abstract][Full Text] [Related]
20. A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.
Dahmcke CM; Steven KE; Larsen LK; Poulsen AL; Abdul-Al A; Dahl C; Guldberg P
Eur Urol; 2016 Dec; 70(6):916-919. PubMed ID: 27417036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]